Things looking better for Bharti Airtel; margin picture good for Dabur: Hemang Jani
Pharma was not just a one-year Covid related story. It is a story where both chronic and non-chronic segments will contribute over the next few years. Within the pack, we like , Divis. Within the midcap, we like Gland Pharma, Aurobindo Pharma, says Hemang…
